Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-08-07), Surgery Partners's 9-Day RSI is 38.88.
The industry rank for Surgery Partners's 9-Day RSI or its related term are showing as below:
FRA:1SP's 9-Day RSI is ranked better than 76.98% of 695
companies
in the Healthcare Providers & Services industry
Industry Median: 50.79
vs FRA:1SP: 38.88
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Surgery Partners 9-Day RSI Related Terms
FRA:1SP vs AVAH, ASTH, ADUS: 9-Day RSI Comparison
For the Medical Care Facilities subindustry, Surgery Partners's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgery Partners 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgery Partners's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Surgery Partners's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgery Partners (FRA:1SP) has a 9-Day RSI of 38.88 as of Aug. 07, 2026. According to the industry distribution chart, Surgery Partners ranks #160 out of 695 companies in the Healthcare Providers & Services industry, placing it in the top 23%.
Is Surgery Partners' 9-Day RSI too high?
Surgery Partners' current 9-Day RSI is 38.88. The Healthcare Providers & Services industry median 9-Day RSI is 50.79. Surgery Partners' value of 38.88 is 23.4% below this industry median. Based on the distribution chart, Surgery Partners ranks #160 out of 695 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Surgery Partners has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Surgery Partners' 9-Day RSI compare to AVAH and ASTH?
According to the Healthcare Providers & Services industry distribution chart, Surgery Partners ranks #160 out of 695 companies for 9-Day RSI. This places Surgery Partners in the top 23% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 50.79. Surgery Partners' value of 38.88 is 23.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 50.79, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgery Partners's current 9-Day RSI of 38.88 is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 50.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgery Partners's current 9-Day RSI is 38.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgery Partners stock overvalued right now?
Based on GuruFocus' analysis, Surgery Partners (FRA:1SP) is currently considered Possible Value Trap. The stock's GF Value™ is €23.00, compared to a current price of €12.80 — trading 44.3% below its estimated fair value. The current 9-Day RSI is 38.88 and 23.4% below the Healthcare Providers & Services industry median of 50.79. Surgery Partners' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Surgery Partners (FRA:1SP), the current 9-Day RSI is 38.88 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgery Partners (FRA:1SP) Overvalued in 2026?
Based on GuruFocus' analysis, Surgery Partners stock appears to be undervalued.
The current stock price of €12.80 is trading 44.3% below its estimated GF Value™ of €23.00.
GuruFocus considers Surgery Partners to be Possible Value Trap.
Key valuation signals for FRA:1SP:
9-Day RSI: 38.88
GF Value™: €23.00 vs. price of €12.80 (44.3% below fair value)
Industry Position: 23.4% below the Healthcare Providers & Services median (#160 of 695)
No single metric tells the full story. See the FRA:1SP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
65GF Score
Get the complete analysis for FRA:1SP
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SP has been successfully added to your 
